Anticoagulant and antithrombotic drugs in pregnancy: What are the anesthetic implications for labor and cesarean delivery

Journal of Perinatology

Volumn 31, Issue 2, 2011, Pages 73-84

  Butwick, A J ^a   Carvalho, B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anticoagulants; antithrombotics; neuraxial anesthesia; pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TICLOPIDINE; TINZAPARIN; WARFARIN;

APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CESAREAN SECTION; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; EMBOLISM; EPIDURAL ANESTHESIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABOR; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OBSTETRIC ANESTHESIA; OBSTETRIC HEMORRHAGE; OSTEOPOROSIS; PARALYSIS; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; REPEATED DRUG DOSE; RISK FACTOR; SINGLE DRUG DOSE; SPINAL ANESTHESIA; SPINAL HEMATOMA; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANESTHESIA, CONDUCTION; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DELIVERY, OBSTETRIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINES AS TOPIC; HEMATOMA, SUBDURAL, SPINAL; HUMANS; MONITORING, PHYSIOLOGIC; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK ADJUSTMENT;

EID: 79551647275     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2010.64     Document Type: Article

References (90)

1. ACOG practice bulletin. Obstetric analgesia and anesthesia. number 36, July 2002 American college of obstetrics and gynecology. Int J Gynaecol Obstet 2002; 78: 321-335.
2. Cohen SE, Subak LL, Brose WG, Halpern J. Analgesia after cesarean delivery: patient evaluations and costs of five opioid techniques. Reg Anesth 1991; 16: 141-149.
3. Harrison DM, Sinatra R, Morgese L, Chung JH. Epidural narcotic and patient-controlled analgesia for post-cesarean section pain relief. Anesthesiology 1988; 68: 454-457.
4. Bloom SL, Spong CY, Weiner SJ, Landon MB, Rouse DJ, Varner MW et al. Complications of anesthesia for cesarean delivery. Obstet Gynecol 2005; 106: 281-287.
5. Hawkins JL, Koonin LM, Palmer SK, Gibbs CP. Anesthesia-related deaths during obstetric delivery in the United States, 1979-1990. Anesthesiology 1997; 86: 277-284.
6. Bucklin BA, HawkinsJL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology 2005; 103: 645-653.
7. Groen RJ, van Alphen HA. Operative treatment of spontaneous spinal epidural hematomas: a study of the factors determining postoperative outcome. Neurosurgery 1996; 39: 494-508, discussion 508-509.
8. Lawton MT, Porter RW, Heiserman JE, Jacobowitz R, Sonntag VK, Dickman CA. Surgical management of spinal epidural hematoma: relationship between surgical timing and neurological outcome. J Neurosurg 1995; 83: 1-7.
9. Kreppel D, Antoniadis G, Seeling W. Spinal hematoma: a literature survey with meta-analysis of 613 patients. Neurosurg Rev 2003; 26: 1-49.
10. Forsnes E, Occhino A, Acosta R. Spontaneous spinal epidural hematoma in pregnancy associated with using low molecular weight heparin. Obstet Gynecol 2009; 113: 532-533.
11. Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M et al Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008; 34: 58-73.
12. Roofthooft E. Anesthesia for the morbidly obese parturient. Curr Opin Anaesthesiol 2009; 22: 341-346.
13. Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J et al Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197: 457 e451-421.
14. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 844S-886S.
15. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT et al Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American society of regional anesthesia and pain medicine evidence-based guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64-101.
16. Clinical guidelines for inhibitors of hemostasis locoregional neuraxial anesthesia spanish society of anesthesiology-resuscitation and pain therapy, division of hemostasis, transfusion medicine, and perioperative fluid therapy. Rev Esp Anestesiol Reanim 2005; 52: 413-420.
17. Gogarten W, Van Aken H, Büttner J, Riess H, Wulf H, Bürkle H. Regional anaesthesia and thromboembolism prophylaxis/anticoagulation\revised recommendations of the German society of anaesthesiology and intensive care medicine. Anaesthesiol Intensivmed 2007; 48: S109-S124.
18. Kozek-Langenecker SA, Fries D, Gutl M, Hofmann N, Innerhofer P, Kneifl W et al Locoregional anesthesia and coagulation inhibitors. recommendations of the task force on perioperative coagulation of the Austrian society for anesthesiology and intensive care medicine. Anaesthesist 2005; 54: 476-484.
19. Nederlandse Vereniging voor Anesthesiologie. Guidelines on neuraxial blockade and antithrombotic therapy. 2003.
20. Societe Francaise d'anesthesie et de reanimation Les blocs perimedullaires chez l'adulte. Recommandations pour la pratique clinique 2006.
21. Vandermeulen E, Singelyn F, Vercauteren M, Brichant JF, Ickx BE, Gautier P. Belgian guidelines concerning central neural blockade in patients with drug-induced alteration of coagulation: an update. Acta Anaesthesiol Belg 2005; 56: 139-146.
22. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79: 1165-1177.
23. Horlocker TT, Wedel DJ. Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the Titanic Anesth Analg 1998; 86: 1153-1156.
24. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA et al Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). RegAnesth Pain Med2003; 28: 172-197.
25. Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998; 338: 1774-1775.
26. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101: 950-959.
27. Ruppen W, Derry S, McQuay H, Moore RA. Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. Anlogy 2006; 105 394 399.
28. Cook TM, Counsell D, Wildsmith JA. Major complications of central neuraxial block: report on the third national audit project of the royal college of anaesthetists. BrJAnaesth 2009; 102: 179-190.
29. Davies JM, Posner KL, Lee LA, Cheney FW, Domino KB. Liability associated with obstetric anesthesia: a closed claims analysis. Anesthesiology 2009; 110: 131-139.
30. Greer IA, Nelson-Piercy C Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407.
31. Maslovitz S, Many A, LandsbergJA, Varon D, Lessing JB, Kupferminc MJ. The safety of low molecular weight heparin therapy during labor. J Matern Fetal Neonatal Med 2005; 17: 39-43.
32. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk Am J Obstet Gynecol 1997; 176: 1062-1068.
33. Kominiarek MA, Angelopoulos SM, Shapiro NL, Studee L, Nutescu EA, Hibbard JU. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications. J Perinatol 2007; 27: 329-334.
34. Lambert JR, Austin SK, Peebles D, Cohen H. Audit of the peri-delivery use of unfractionated heparin in women on therapeutic low-molecular weight heparin. Br J Haematol 2008; 142: 453-456.
35. Cleary-Goldman J, Bettes B, Robinson JN, Norwitz E, Schulkin J. Thrombophilia and the obstetric patient. Obstet Gynecol 2007; 110: 669-674.
36. Krombach JW, Dagtekin O, Kampe S. Regional anesthesia and anticoagulation. Curr Opin Anaestheio 2004 17 427 433.
37. Llau JV, De Andres J, Gomar C, Gomez-Luque A, Hidalgo F, Torres LM. Anticlotting drugs and regional anaesthetic and analgesic techniques: comparative update of the safety recommendations. Eur J Anaesthesiol 2007; 24: 387-398.
38. Akkad A, Oppenheimer C, Mushambi M, Pavord S. Intrapartum care for women on full anticoagulation. Int J ObstetAnesth 2003; 12: 188-192.
39. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359-374.
40. Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacody-namics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 173: 1240-1245.
41. Chunilal SD, Young E, Johnston MA, Robertson C, Naguit I, Stevens P et al The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002; 87: 92-97.
42. Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128: 593-601.
43. Hemker HC, Beguin S. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis 1990; 20(Suppl 1): 81-92.
44. Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Blood Coagul Fibrinolysis 1998; 9: 571-580.
45. Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A et al Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452.
46. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26(Suppl 1): 31-38.
47. Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost 2004; 92: 791-796.
48. Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101: 1307-1311.
49. Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul Fibrinolysis 1998; 9: 343-350.
50. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113-1117.
51. Lebaudy C, Hulot JS, Amoura Z, Costedoat-Chalumeau N, Serreau R, Ankri A et al Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther 2008; 84: 370-377.
52. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20-80 mg. J Clin Pharmacol 1988; 28: 609-618.
53. Eriksson BI, Soderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398-401.
54. Hammerstingl C, Omran H, Tripp C, Poetzsch B. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study. Thromb Haemost 2009; 101: 325-332.
55. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and standardization committee communications: on behalf of the control of anticoagulation subcommittee of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb Haemost 2002; 87: 163-164.
56. Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A. Thromboprophylaxis following caesarean section-a comparison of the antithrombotic properties of three low molecular weight heparins-dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001; 86: 1374-1378.
57. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109: 1-11.
58. Boneu B, Necciari J, Cariou R, Sie P, Gabaig AM, Kieffer G et al Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-1473.
59. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost 2007; 97: 496-497.
60. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569-1570.
61. Lagrange F, Vergnes C, Brun JL, Paolucci F, Nadal T, Leng JJ et al. Absence ofplacental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87: 831-835.
62. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350: 1914-1915.
63. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632.
64. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-3076.
65. Rymark P, Berntorp E, Nordsjo P, Liedholm H, Melander A, Gennser G. Low-dose aspirin to pregnant women: single dose pharmacokinetics and influence of short term treatment on bleeding time. J Perinat Med 1994; 22: 205-211.
66. Orlikowski CE, Payne AJ, Moodley J, Rocke DA. Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects. BrJAnaesth 1992; 69: 159-161.
67. Kinouchi K, Fujita T, Narahara C, Kitamura S. Platelet function in pregnant women receiving aspirin and dipyridamole. J Anesth 2000; 14: 115-118.
68. James AH, Jamison MG, Biswas MS, Brancazio LR, Swamy GK, Myers ER. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006; 113: 1564-1571.
69. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
70. ThebaultJJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999; 25(Suppl 2): 3-8.
71. Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999; 25(Suppl 2): 9-14.
72. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999; 25(Suppl 2): 25-28.
73. Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost 1999; 25(Suppl 2): 29-33.
74. Picard-Fraire C Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function. Thromb Res Suppl 1983; 4: 119-128.
75. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-338.
76. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-1672.
77. Kam PC, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003; 58: 28-35.
78. O'Reilly RA, Aggeler PM. Determinants of the response to oral anticoagulant drugs in man. Pharmacol Rev 1970; 22: 35-96.
79. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest2008; 133: 160S-198S.
80. Marder VJ, Shulman NR. Clinical aspects of congenital factor VII deficiency. Am J Med 1964; 37: 182-194.
81. Brooks C, Rutherford JM, GouldJ, Ramsay MM, James DK. Warfarin dosage in postpartum women: a case-control study. BJOG 2002; 109: 187-190.
82. James AH. Thromboembolism in pregnancy: recurrence risks, prevention and management. Curr Opin Obstet Gynecol 2008; 20: 550-556.
83. James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 2009; 29: 326-331.
84. Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med 2009; 4: 137-145.
85. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109: 918-926.
86. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 37-48.
87. Ng HJ, Crowther MA. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol 2006; 43: S77-S83.
88. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br JHaematol 2002; 116: 178-186.
89. Lauritzen B, Hedner U, Johansen PB, Tranholm M, Ezban M. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. J Thromb Haemost 2008; 6: 804-811.
90. Firozvi K, Deveras RA, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol 2006; 81: 582-589.